Filing Details
- Accession Number:
- 0001203311-21-000090
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-12-09 18:49:51
- Reporting Period:
- 2021-12-07
- Accepted Time:
- 2021-12-09 18:49:51
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1060736 | Seagen Inc. | SGEN | Biological Products, (No Disgnostic Substances) (2836) | 911874389 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1167496 | B Clay Siegall | 21823 30Th Drive Se Bothell WA 98021 | President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-12-07 | 1,650 | $26.10 | 670,822 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-12-07 | 1,650 | $146.54 | 669,172 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2021-12-07 | 12,238 | $26.10 | 681,410 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-12-07 | 12,238 | $147.83 | 669,172 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2021-12-07 | 14,691 | $26.10 | 683,863 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-12-07 | 14,691 | $148.27 | 669,172 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2021-12-07 | 11,522 | $26.10 | 680,694 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-12-07 | 11,522 | $149.56 | 669,172 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2021-12-07 | 5,348 | $26.10 | 674,520 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-12-07 | 5,348 | $150.38 | 669,172 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2021-12-07 | 1,650 | $0.00 | 1,650 | $26.10 |
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2021-12-07 | 12,238 | $0.00 | 12,238 | $26.10 |
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2021-12-07 | 14,691 | $0.00 | 14,691 | $26.10 |
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2021-12-07 | 11,522 | $0.00 | 11,522 | $26.10 |
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2021-12-07 | 5,348 | $0.00 | 5,348 | $26.10 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 180,144 | 2022-08-20 | No | 4 | M | Direct | |
| 167,906 | 2022-08-20 | No | 4 | M | Direct | |
| 153,215 | 2022-08-20 | No | 4 | M | Direct | |
| 141,693 | 2022-08-20 | No | 4 | M | Direct | |
| 136,345 | 2022-08-20 | No | 4 | M | Direct |
Footnotes
- Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $146.02 to $146.91. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $147.09 to $148.08. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $148.09 to $149.07. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $149.10 to $150.09. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $150.10 to $151.03. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Options vested at a rate of 25% on 8/20/13 and monthly thereafter until all the options were fully vested on 8/20/16.
Billionaire Hedge Funds
